You need to be logged in to view this video
XDNA ETF: CRISPR Curing Disease and Upcoming Catalysts
Released on Tuesday, September 27, 2022•ETFs
CRISPR technology has had two watershed moments this summer indicating that it is about change healthcare as we know it. Learn about the upcoming catalysts for publicly traded gene editing companies. At its core, CRISPR is a pair of biological scissors that cut and replace genes in living organisms' cells. It has the potential to disrupt virtually every facet of our lives, from curing genetic diseases, detecting and treating cancers, treating HIV, to even bioengineering new crops and plants to feed the world's growing population.
Kevin Kelly is responsible for product design, structuring, managing retail and institutional investment research, and capital markets. He also serves as the CEO of Kelly Benchmark Indexes, the index provider, and sponsor of the SRVR and INDS ETFs. In September 2014, Nasdaq named Mr. Kelly an ETF Insider, and he is a recognized leader in ETF design, distribution and growth with his extensive track record of launching multi-billion-dollar ETFs. Mr. Kelly's thought leadership on markets, derivatives, e-commerce, and technology can be found weekly in top media outlets.
Filter By Category
Filter By Keywords